Share: 
Status: 
Active
Rating: 
Average: 3.5 (2 votes)
3.5

CHEST 2016: Understanding the Role of Targeted Biologic Therapies in the Treatment of Patients with Moderate-to-Severe, Persistent Asthma

Course description

This CME program focuses on content presented during the CHEST 2016 Annual Meeting in Los Angeles, California on October 22 - 26, 2016 and will  address clinical decision-making for the management of patients with asthma. The expert faculty of this program will discuss conference highlights and provide a comprehensive analysis of clinical decision-making in patients with asthma. They will discuss the effectiveness of communicating therapeutic decisions with patients. This program will give physicians a better understanding of when to implement data-driven, patient-specific treatment plans to improve outcomes for patients with asthma.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of allergists/immunologists, pulmonologists, primary care physicians, and other healthcare clinicians responsible for the care of patients with asthma.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be able to:

  1. Review the pathogenesis of asthma, including the role of biomarkers.
  2. Evaluate current and emerging targeted therapies for the treatment of moderate-to-severe asthma presented at CHEST 2016.
  3. Incorporate patient education into individualized treatment plans to improve patient adherence and overall quality of life for patients with moderate-to-severe asthma.

FACULTY

Reynold A. Panettieri, Jr, MD
Robert L. Mayock and David A. Cooper Professor of Medicine Director
Airways Biology Initiative Adjunct Professor
Wistar Institute Deputy Director
Center of Excellence in Environmental Toxicology
Perlman School of Medicine University of Pennsylvania Pulmonary
Allergy and Critical Care Division
Philadelphia, PA

Sidney Braman, MD
Professor Medicine
Director, Pulmonary Disease Management
Division of Pulmonary Critical Care and Sleep Medicine
Ichan School of Medicine at Mount Sinai
New York, NY

Stephen J. Teach, MD, MPH
Chair of the Department of Pediatrics
George Washington University School of Medicine
Children’s National Medical Center
Washington, DC

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Reynold A. Panettieri, Jr, M.D.

Consultant/Advisor: AstraZeneca and Johnson & Johnson Pharmaceutical Company

Grant/Research Support: Gilead; Johnson and Johnson Pharmaceutical Company; Merck & Co., Inc.; Roche Molecular Systems Inc. and sanofi-aventis U.S. LLC

Stephen J. Teach, MD, MPH

Consultant/Advisor: Novartis AG

Sidney Braman, MD

Consultant/Advisor: Boehringer-Ingelheim GmbH; MENA Pharmaceutical Manufacturing Congress; GlaxoSmithKline and Teva Pharmaceutical Industries

Speaker's Bureau: Genentech, Inc.

Non-faculty: Sandra Breslow; Alison Kemp; Leah Johnson; Bernard M. Abrams, MD; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Nicole Brestowski; Chelsey Benedek; and Megan Gentile hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Genentech, Inc. and Teva Pharmaceuticals Industries Ltd.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, Genentech, Inc., and Teva Pharmaceuticals Industries Ltd. do not recommend the use of any agent outside of the labeled indications.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Credits & accreditation
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
12/06/2016
Course expires: 
12/05/2017
Please login or register to take this course.